

# Press Release

## Cellzome Strengthens Management Team with New Hires from UCB Celltech

**Boston, USA, 25<sup>th</sup> September 2008** – Cellzome Inc., the drug discovery company focused on kinase-targeted treatments for inflammatory diseases, today announces the appointments of Oliver Rausch PhD as Senior Director of Biology and Andrew Ratcliffe PhD as Director of Chemistry.

The appointments follow the announcement earlier this month of Cellzome's landmark agreement with GSK to develop novel therapies for inflammatory diseases using the company's kinase expertise.

Oliver Rausch has ten years' experience in the pharmaceutical industry, five of which were with UCB Celltech, most recently as Director of Biology. During his tenure at UCB Celltech, Oliver worked predominantly in the field of inflammation, researching cell signaling targets such as receptors and kinases. In the last two years, Oliver was a core member of UCB's "Centre of Excellence Team" for inflammation where he was responsible for identifying and establishing the therapeutic area's future small molecule project portfolio. Oliver holds a PhD in Biochemistry and Cell Biology from the Institute of Cancer Research in London.

Andrew Ratcliffe has extensive drug discovery experience in inflammatory/respiratory diseases. He has been with UCB Celltech for nine years, six of which were as Associate Director of Medicinal Chemistry. He has a track record of transitioning candidate drugs from research to development and was responsible for taking Celltech's CDP323 product into development for multiple sclerosis where it is currently in Phase II trials in collaboration with Biogen. Prior to UCB Celltech, Andrew was with Rhône Poulenc Rorer for nine years. He holds a PhD in chemistry from Bath University.

Commenting on the appointments, Tim Edwards, CEO of Cellzome, said: "We are delighted to welcome Oli and AJ to the Cellzome management team as we develop our pipeline of kinase-targeted drug candidates. Their areas of expertise will be of great value, and they have already made a strong contribution."

-Ends-

**For further information please contact:**

**Cellzome:**

Tim Edwards  
Chief Executive Officer  
Tel: +49 (0) 6221-137 57-100  
press@cellzome.com

**Media Contact:**

Hogarth Partnership  
Sarah MacLeod  
Tel: +44 (0) 207 357 9477  
SMacleod@hogarthpr.co.uk

**About Cellzome Inc.**

Cellzome is a privately-owned drug discovery company identifying a new generation of kinase-targeted drugs to treat inflammatory diseases. Its pipeline of small-molecule therapeutics is driven by *Kinobeads*<sup>TM</sup>, a proprietary technology for studying simultaneously multiple kinases in their native state, in relevant cell types.

Cellzome is applying its distinctive *Kinobeads*<sup>TM</sup> technology to the discovery and development of novel, selective, small-molecule kinase inhibitors targeting key inflammatory mediators such as PI3K $\gamma$  and  $\delta$ , Zap-70, Jak3 and mTOR, as potential oral therapeutics for rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease, psoriasis and asthma. Cellzome has also identified potent and selective inhibitors of LRRK2, a target implicated in Parkinson's disease which has proved intractable in many standard screens.

In September 2008 Cellzome and GlaxoSmithKline announced a significant, worldwide, strategic alliance to discover, develop and market novel kinase-targeted therapeutics to treat inflammatory diseases, using Cellzome's *Kinobeads*<sup>TM</sup> technology. Cellzome also has a collaboration with Johnson & Johnson focused on the discovery of novel medicines for the treatment of Alzheimer's disease.

Cellzome's holding company is domiciled in the US and it employs about 90 people at its two operating subsidiaries in Cambridge, UK and Heidelberg, Germany. To learn more about Cellzome, please visit the website: [www.cellzome.com](http://www.cellzome.com).